Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives, Dan Lynch, and ...

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting results this Thursday morning. Here’s what you need to know.

The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...

For reference, Seeking Alpha's Quant system is driven by powerful computer processing and SA's special 'Quantamental' ...

US pharma major Bristol Myers Squibb and Bain Capital announced the creation of a new independent biopharmaceutical company ...

AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-positioned,” while Novartis and Roche look more at risk, ...

Piper Sandler lowered the firm’s price target on Bristol Myers (BMY) to $64 from $66 and keeps an Overweight rating on the shares ahead of ...

Two diabetes drugs could become more affordable for Maryland residents, following a study by the Prescription Drug ...

The clinical benefits of exercise-based cardiac rehabilitation have been less clear for patients with Afib. A meta-analysis ...

Merck (MRK) is cutting $3 billion from its annual expenses as it prepares for generic competition to its blockbuster cancer drug, Keytruda.

Merck has launched a sweeping cost-cutting effort designed to save $3 billion annually by the end of 2027, the company said ...